| Therapy | Indication | Vector / Approach |
| Zolgensma (onasemnogene abeparvovec) | Spinal muscular atrophy (SMA) type 1 | AAV9-SMN1 |
| Luxturna (voretigene neparvovec) | RPE65-mediated retinal dystrophy | AAV2-RPE65 |
| Zynteglo (betibeglogene autotemcel) | Transfusion-dependent β-thalassemia | Lentiviral β-globin (autologous HSC) |
| Skysona (elivaldogene autotemcel) | Cerebral adrenoleukodystrophy | Lentiviral ABCD1 (autologous HSC) |
| Hemgenix (etranacogene dezaparvovec) | Hemophilia B | AAV5-FIX |
| Roctavian (valoctocogene roxaparvovec) | Hemophilia A | AAV5-FVIII |
| CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Carvykti) | B-cell malignancies (ALL, DLBCL, MCL, MM) | Autologous T cells + anti-CD19/BCMA CAR |
Pipeline Highlights
- Cystic fibrosis: AAV-CFTR inhaled (Phase 2/3).
- Sickle cell: CRISPR-Cas9 (exa-cel, Casgevy – approved UK/US 2023) editing BCL11A enhancer → HbF induction.
- Duchenne muscular dystrophy: Micro-dystrophin AAV (Phase 3).
- Phenylketonuria: AAV-PAH (Phase 2).
- Cardiac: AAV-SERCA2a, CRISPR for arrhythmogenic cardiomyopathy.
- HIV: CCR5 editing (EBT-101, CRISPR excision of provirus).
Challenges
- Immunogenicity (pre-existing AAV antibodies exclude many patients).
- Durability (episomal AAV dilution in dividing cells).
- Off-target editing (CRISPR).
- Cost ($1–3M per treatment); access equity.
- Manufacturing complexity, regulatory pathways.
Gene therapy is transitioning from rare-disease niche to broader therapeutic modality.
Genetic Disorders - Related Articles